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EXOSC8 mutations alter mRNA metabolism and
cause hypomyelination with spinal muscular
atrophy and cerebellar hypoplasia
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The exosome is a multi-protein complex, required for the degradation of AU-rich element
(ARE) containing messenger RNAs (mRNAs). EXOSC8 is an essential protein of the exosome
core, as its depletion causes a severe growth defect in yeast. Here we show that homozygous
missense mutations in EXOSC8 cause progressive and lethal neurological disease in 22 infants
from three independent pedigrees. Affected individuals have cerebellar and corpus callosum
hypoplasia, abnormal myelination of the central nervous system or spinal motor neuron
disease. Experimental downregulation of EXOSC8 in human oligodendroglia cells and in
zebrafish induce a specific increase in ARE mRNAs encoding myelin proteins, showing that
the imbalanced supply of myelin proteins causes the disruption of myelin, and explaining
the clinical presentation. These findings show the central role of the exosomal pathway in
neurodegenerative disease.
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T
he degradation of messenger RNAs (mRNAs) is
an important regulatory step, which controls gene
expression1,2. Unstable mammalian mRNAs contain AU-
rich elements (AREs) within their 30-untranslated regions. Rapid
degradation of ARE-containing RNAs is performed by a multi-
protein complex, the exosome3,4. The versatility and specificity of
the exosome regulate the activity and maintain the fidelity of gene
expression5. Both in yeast and humans, nine proteins organize
the ‘exosome core’ in a two-layered ring. The central hexamer
channel is composed by six subunits (Rrp41p/EXOSC4, Rrp46p/
EXOSC5, Rrp45p/PM/Scl-75/EXOSC9, Rrp42p/EXOSC7, Mtr3/
EXOSC6 and Rrp43p/Oip2/EXOSC8), while the cap consists of
three proteins (Rrp4/EXOSC2, Rrp40/EXOSC3 and Csl4/SOCS4)4,6.
The exosome degrades RNA starting at the 30-end by an
exoribonucleolytic function and it also has an endoribonucleolytic
function7,8. The catalytic activity of the exosome core is provided
through the association with other proteins (RRP44/DIS3, RRP6/
PM/Scl-100/EXOSC10 ribonucleases)1. ARE recognition requires
ARE-binding proteins that interact with the exosome for
recruitment, thereby promoting the rapid degradation of target
RNAs9.
The human exosome also regulates gene expression via diverse
RNA processing reactions10. Many cellular RNAs that play key
roles in important cellular processes such as translation (ribosomal
RNAs, transfer RNAs and small nucleolar RNAs) and mRNA
splicing (small nuclear RNAs) are produced as precursor molecules
that are trimmed from their 30-ends by the human exosome11.
This complex organization of the exosome provides the versatility
needed to cope with the huge variety of RNA substrates
in the cell12. However, detailed in vivo analyses are technically
challenging and many questions remain unresolved.
Here we report that deficiency of a core component of the
human exosome leads to severe infantile overlap phenotype of
psychomotor deficit, cerebellar and corpus callosum hypoplasia,
hypomyelination and spinal muscular atrophy (SMA).
Results
Clinical presentation in 22 patients from three pedigrees. First
we studied a large Hungarian family of Roma ethnic origin, where
18 children presented between 2–4 months of age with failure to
thrive, severe muscle weakness, spasticity and psychomotor
retardation. Vision and hearing were impaired in all patients and
deterioration was usually triggered by inter-current infections. All
affected children died of respiratory failure before 20 months of
age (Fig. 1a, Supplementary Table 1). Detailed diagnostic workup
excluded known metabolic, neurodegenerative and common
genetic disorders. Electrophysiology was performed in one patient
only (P1-V:10) and was not conclusive. Brain magnetic resonance
imaging (MRI) showed variable abnormalities including vermis
hypoplasia, immature myelination, cortical atrophy and thin
corpus callosum (Supplementary Table 1).
EXOSC8 mutations were also identified in two additional
patients from an independent Hungarian Roma family (Fig. 1b,c)
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Figure 1 | Pedigrees with clinical presentation and brain MRI. (a) Pedigree of the original Hungarian Roma family. *DNA of these family members
was used for mutation analysis. (b) Pedigree 2, Hungarian Roma ethnic origin. (c) Patient P-II:10 at age 6 months. (d) MRI of patient P-II:10-detected
immature myelination, which was consistent with the patient’s age (5 months, axial T2 image) A moderately thin corpus callosum was seen in the
sagittal T2 image of the same patient. The extra-cerebral cerebrospinal fluid spaces were satisfactory in appearance. (e) Pedigree 3, a consanguineous
Palestinian family. (f) Brain MRI of the affected siblings revealed mega cisterna magna and hypoplasia of the cerebellum and corpus callosum.
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and in two affected siblings from a consanguineous Arab–
Palestinian family (Fig. 1e). The clinical presentation of the
additional patients was compatible with a progressive, infantile
onset neurological disease, presenting with severe muscle
weakness, respiratory problems, developmental delay and early
death (Supplementary Table 1). Vermis hypoplasia was more
prominent in the third pedigree (Fig. 1f), while immature
myelination was reported in pedigree 2 (Fig. 1d). Weakness in
P3 was proximal more than distal with attendant tongue
fasciculations. Motor neuronopathy was noted on electrophysio-
logical examination in P3-II:1.
Muscle biopsy in patient P1-V:10 at 5 months of age detected
variations in fibre size and increased subsarcolemmal nuclei, but
no signs of SMA. Cytochrome c oxidase (COX) negative
fibres were noted on histochemical staining and activities of
respiratory chain complexes I and IV were moderately decreased
(Supplementary Note 1). We excluded mitochondrial DNA
(mtDNA)-mediated mechanisms for multiple respiratory chain
enzyme deficiency (mtDNA deletion/depletion, point mutations).
Muscle biopsy of another patient (P3-II:1) at 2 years of age showed
groups of atrophic and hypertrophic fibres compatible with SMA.
Autopsy in eight patients detected profound lack of myelin in
the cerebral and cerebellar white matter and in the spinal cord,
predominantly affecting the descending lateral fibre tracts, while
myelination was normal in the peripheral nerves (Fig. 2a–n). The
lack of myelin in the brain and spinal cord (Fig. 2g,n) was
similarly severe as observed in a patient with Pelizaeus–
Merzbacher disease (PMD) (Fig. 2m). However myelin basic
protein (MBP) staining was stronger in our patients (Fig. 2k) as
compared with the PMD patient (Fig. 2j), indicating the different
composition of defective myelin. Autopsy was not performed in
the deceased patient from P3-II:1, but MRI at 5 years of age did
not indicate hypomyelination.
Homozygosity mapping and exome sequencing. Genome-Wide
Human SNP Array 6.0 (Affymetrix) in six affected family
members of the first pedigree revealed two broad regions of
homozygosity on chromosome 13 (36212278–37767059 bp, size:
B1.55Mb; and 43243791-44640995 bp, size: 1.4Mb) (Fig. 3a)13.
Exome sequencing in genomic DNA of two patients
(P1-V:10, P1-V:29) identified seven shared rare (major allele
frequencyo0.01) homozygous protein altering variants (Fig. 3b),
but only one, the c.815G4C, p.Ser272Thr mutation in EXOSC8
(Gene ID:11340, NC_000013.10, mRNA:NM_181503.2) (Fig. 3d)
was located in the larger B1.55Mb homozygous region. This
mutation affects a conserved amino acid and resulted in
significantly decreased EXOSC8 protein (Fig. 3e–g), and no
other variants were found in complementary DNA (cDNA) of
EXOSC8. The location of the mutation implies that it may affect
the opening of the RNA channel within the exosome, where
funneling of RNAs takes place in single-stranded conformation
by an unwinding pore (Fig. 3f). This mutation segregated with the
disease in 19 individuals within the family (8 affected:
homozygous; 11 unaffected: heterozygous or wild type)
(Fig. 1a). The same homozygous mutation was identified in two
siblings with an identical clinical presentation from a second
Hungarian Roma family (pedigree 2) from the same region. None
of the other six homozygous mutations detected by exome
sequencing of the index patients in pedigree 1 were homozygous
in the patients in pedigree 2, thus excluding the possibility that
these other mutations were causing the disease.
To estimate the frequency of this mutation in Roma
population, mutation testing was carried out in 63 anonymized
Roma controls from Bulgaria, of whom 33 were homozygous for
an identical 229522 bp chromosome 13q13.1 haplotype (rs582091
to rs7327020) around c.815G4C, p.Ser272Thr (Supplementary
Note 2). This screening identified two heterozygotes, that is,
carrier rates ofB3% in the general Roma population, which is in
agreement with the frequency rates of other Roma disease causing
mutations14,15.
A different missense mutation, c.5C4T, p.Ala2Val was
identified on exome sequencing in two affected siblings of a
consanguineous Palestinian family (pedigree 3) with SMA,
cerebellar and corpus callosum hypoplasia (Fig. 3c). Homo-
zygosity mapping in this pedigree resulted in the identification
of three disease-linked genomic regions, one of them was an
8.4Mb spanning chr13:31642481-40039652 (Hg19) (rs7996548 to
rs12873765). Exome sequencing in genomic DNA of P3:II-3
identified four shared rare (minor allele frequencyo0.01)
homozygous protein altering variants but only one of them
affected an evolutionary conserved residue (Fig. 3e). This variant,
c.5C4T, p.Ala2Val (chr13: 37574947 C4T) in the EXOSC8 gene
segregated with the disease in the family, was not present in
dbSNP138 and was also absent from the 6503 exome analyses
available at the Exome Variant Server, NHLBI GO Exome
Sequencing Project (ESP), Seattle, WA, USA (URL: http://
evs.gs.washington.edu/EVS/) (accessed on 26 January 2014) and
in fibroblasts of the patient, immunoblotting detected severely
decreased EXOSC8 protein (Fig. 3d). The c.5C4T mutation in
the second codon of EXOSC8 might therefore either interfere
with the Kozak consensus sequence and/or cause mRNA
instability probably through interference with the 50 mRNA
capping mechanism16,17. Nonsense-mediated messenger decay
could be excluded because mutant copy numbers could not be
increased after 300mM puromycin treatment (Supplementary
Fig. 1).
Downregulation of the yeast ortholog of human EXOSC8.
RRP43, the yeast ortholog of the human EXOSC8 has a low degree
of conservation with the human gene, lacking the C-terminal
region, where the human mutation p.Ser272Thr is located. Based
on the observed mitochondrial dysfunction in patient V:10 we
investigated whether a defect in the yeast ortholog of EXOSC8
affects mitochondrial function. We took advantage of a pro-
moter-shutoff tetRRP43 strain18. Wild-type and tetRRP43 cells
were grown on non-fermentable carbon sources in the presence/
absence of doxycycline 0.125 mgml 1. Treatment with
doxycycline caused a strong growth reduction on glucose of
tetRRP43 while only a slight reduction on glycerol suggesting that
RRP43 downregulation does not primarily affect oxidative
phosphorylation capacity (Fig. 4a). We speculate that in the
presence of glycerol, that slows cell growth and metabolic rate, the
exosome complex is able to maintain a basal RNA abundance,
despite the downregulation of tetRRP43. Furthermore, the
reduced RRP43 gene expression caused significantly decreased
respiration that was paralleled by a decreased amount of
mitochondrial cytochromes compared with wild type, although
their structural integrity was not affected (Fig. 4c). No difference
in mitochondrial translation rate was observed between wildtype
and tetRRP43 mutant in the presence/absence of doxycycline
(Fig. 4d) suggesting that reduced expression of RRP43/EXOSC8
may have a secondary effect on mitochondrial function, possibly
due to disturbed mRNA processing of mitochondrial genes
containing ARE elements19.
Increased gene expression of selected ARE-containing mRNAs.
After the exclusion of a primary mitochondrial phenotype in
RRP43 depleted yeast we studied the possible mRNA targets of
EXOSC8 in human cells. EXOSC8 encodes a 30–50 exoribonu-
clease that specifically interacts with ARE-containing mRNAs
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Figure 2 | Autopsy findings. (a–h) Cerebral cortex and white matter in autopsy of patient V:3 (pedigree 1). (a,b) Thickness of the white matter is
significantly reduced, while the cortex is relatively well preserved. Black arrow: thickness of the cortex from the pia to the cortex/white matter borderzone;
grey arrow: thickness of the white matter from the borderzone to the ependymal lining (Hematoxylin and eosin (H&E) staining); extensive astrogliosis
(pale nuclei; white arrowhead) and reduced frequency of oligodendrocytes (dark round nuclei; black arrowhead). (c) Cerebellar cortex is relatively well
preserved, but there is a microvacuolation of the underlying white matter within the cerebellar folia (H&E staining). (d) Reactive astrocytes (arrows) within
the cerebellar white matter (vimentin immunohistochemistry). (e,f) Purkinje cell axonal torpedos (modified Bielschowsky silver method) (e) and
neurofilament antibodies (f) indicating the loss of axonal connections. (g) Loss of myelin within the cerebellar white matter (Luxol Fast Blue). (h) Relative
preservation of the myelin staining on myelin basic protein immunohistochemistry. (i–n) Spinal cord: normal control (i,l), Pelizaeus–Merzbacher
disease (j,m) and EXOSC8 deficiency (patient V:20) (k,n). In EXOSC8 deficiency, myelin basic protein is present–apart from the longitudinal descending
fibre tracts (k, *)–while it is completely absent in Pelizaeus–Merzbacher disease (j). Myelin is well preserved within the peripheral nerve roots
(m,n, arrowheads), while indicates severe loss of myelin in both conditions within the spinal cord (m,n, Luxol Fast Blue).
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suggesting that a defect in this protein might specifically alter
degradation of ARE mRNAs. Based on the clinical presentation of
predominant white matter abnormalities, cerebellar and corpus
callosum hypoplasia, SMA and mitochondrial dysfunction in our
patients we searched the ARE Database (ARED,http://
brp.kfshrc.edu.sa/ARED/ ) with keywords ‘myelin’, ‘ataxia’,
‘spinal motor neuron’ and ‘mitochondrial’ (Supplemen-
tary Note 3). We studied mRNA levels of 18 selected ARE-
containing and 16 non-ARE-containing genes in myoblasts and
fibroblasts of our patients and in human control cells and oli-
godendroglia cells (MO3.13) before and after small-interferring
RNA (siRNA) downregulation of EXOSC8 (Fig. 5). EXOSC8-
deficient patient myoblasts (P1-V:10) revealed a significant 2.99-
fold increase (P¼ 0.0055) inMBP gene expression compared with
control human myoblasts (average of three different control cell
lines), while the expression of the other selected genes did not
show a significant change (Fig. 5a, Supplementary Table 2).
EXOSC8 downregulation in myoblasts significantly increased
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Figure 3 | Homozygosity mapping, exome sequencing, EXOSC8 mutation analysis and immunoblotting for EXOSC8. (a) Genome-Wide Human SNP
Array 6.0 (Affymetrix) was performed in six affected (P1-V:2, P1-V:10, P1-V:20, P1-V:27, P1-V:29, P1-VI:3) and one unaffected family members (P1-IV:14).
Homozygosity mapping indicated two regions of homozygosity on chromosome 13 spanning from 36214563 bp to 37767059bp (rs7327540 to
rs11147637) and 43243791 bp to 44640995bp (rs9533208 to rs9567354). (b) Exome sequencing detected 2,294 and 2,274 rare/novel single nucleotide
variants (SNV) of which 184 were shared homozygous variants in patients P1-V:10 and P1-V:29; seven were protein altering, one of which was in the region
of homozygosity in EXOSC8. SNV-Varscan parameters (*) minimum total coverageZfivefold, minimum variant coverageZonefold, minimum quality410;
Indel-Dindel output filter minimum variant coverage Z4. (a) Variants with position within targets (Illumina Truseq 62Mb) ±500bp, seen on both
(forward and reverse) strands and (SBVs only) variant allele frequency 424%. (b) Variants that match 1,000 Genomes (Feb2012) and/or NHLBI 6500
exomes and/or In-house 334 exomes with MAF40.01. (c) Confirmatory Sanger Sequencing indicated the presence of the homozygous c.815G4C,
p.Ser272Thr mutation in an affected patient (A) and heterozygously in her mother (U). This rare variant is listed as rs36027220 with a minor allele
frequency ofo0.01 (ref database) and was present also in pedigree 2. In pedigree 3 another homozygous mutation c.5C4T, p.Ala2Val has been identified
(control - upper chromatogram, patient - lower chromatogram). (d) Immunoblotting showing EXOSC8 protein in control myoblasts (C. M.) and in
myoblasts of P1-V:10 (P. M.); control fibroblasts (C. F.) and in fibroblasts of P3-II:1 (P. F.) using b-Actin or GAPDH as a loading control. (e) Both mutations
alter conserved amino acids. (f) Crystal structure of the human exosome complex. The cap proteins are indicated in green (EXOSC3 light green) and the
core proteins in grey. EXOSC8 highlighted in pink and the mutated residues (Ser 272, Ala2) are marked as black (arrowhead).
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expression of two ARE-containing myelin-related genes: MBP
(46.5-fold, P¼ 0.0167) (Fig. 5b, Supplementary Table 2) and
myelin-associated oligodendrocyte basic protein (MOBP 48.5-
fold, P¼ 0.0158, Supplementary Table 2). However, no significant
change was detected in mRNA levels of any of the other tested
AU-rich and non-AU-rich genes (Supplementary Table 2). Based
on the selective effect of EXOSC8 downregulation on oligoden-
droglia-related genes, quantitative reverse transcription-PCR
(qRT-PCR) analysis has been performed in EXOSC8 down-
regulated human MO3.13 oligodendroglia cells (kind gift of Prof.
Nalbantoglu, McGill). In support of our previous findings, we
detected a highly significant increase in expression of MBP
(4100-fold, P¼ 0.013) (Fig. 5c), which led to increased MBP
protein levels in differentiated oligodendroglia cells detected by
immunostaining and immunoblotting (Fig. 5h–j).
In patient fibroblasts (P3-II:1) we detected a significant
Bfourfold increase (P¼ 0.01984) in the expression of SMN1,
which is the major causative gene leading to SMA (Fig. 5d). No
significant change was detected in the other studied genes (16
ARE and 16 non-ARE mRNAs), suggesting that only a subset of
ARE transcripts was significantly affected by EXOSC8 dysfunc-
tion in both cell types. EXOSC8 downregulation in fibroblasts
resulted in significant increase of SMN1 (2.72-fold, P¼ 0.00038),
MBP (6.74-fold, P¼ 0.01936) and MOBP (2.48-fold, P¼
0.04767), but no significant change was detected in mRNA levels
of any of the other tested AU-rich and non-AU-rich genes
(Fig. 5e, Supplementary Table 3).
Morpholino knock down of exosc8 in zebrafish. To study the
link between reduced EXOSC8 and the human disease we
established a zebrafish model for EXOSC8 deficiency. Zebrafish
has previously been used to model human demyelination
and pontocerebellar dysfunction20–22. We selected two different
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Figure 5 | RT-PCR studies in patient myoblasts, control myoblasts and human oligodendroglia cells and immunohistochemistry and immunoblotting
for myelin basic protein (MBP) in human oligodendroglia cells. (a) Quantitative PCR of MBP, PMP22 and EIF2B2 in patient and control myoblasts.
The gene expression of MBP shows significant increase (fold change42.99, P¼0.0055) while no other gene expression is altered. C. M., control
myoblasts; P. M., P1-V:10 myoblasts. (b) Relative quantification of MBP expression in human myoblasts treated with EXOSC8 siRNA. Downregulation of
EXOSC8 resulted in increased expression of MBP and MOBP, but not in the non-AU-rich control genes PMP22 and EIF2B2. C. M.,control myoblasts; CNTR.,
control; PP. M., P1-V:10 myoblasts;. (c) RT-PCR detected4100-fold increase of MBP mRNA in human oligodendroglia cells after EXOSC8 downregulation,
but no significant change was observed in mRNAs of the non AU-rich control genes PMP22 and EIF2B2. Unpaired t-test was used for statistical
analysis. Statistically significant changes are marked with *. Error bars show standard deviation of three experimental repetitions. (d) Quantitative PCR of
SMN1, BICD2 and IGHMBP2 in patient and control fibroblasts. The gene expression of SMN1 shows significant increase (Bfourfold change, P¼0.01984)
while no other gene expression is altered. C. F., control fibroblasts; P. F., P3-II:1 fibroblasts. (e) Quantification of ARE-containing and non-ARE-containing
genes in human fibroblasts after 3 days EXOSC8 downregulation detected significant increase in SMN1 and MBP. (f) Immunoblotting confirmed that
EXOSC8 siRNA downregulation resulted in severe depletion of this protein in both myoblasts (M) and (g) fibroblasts (F). (h) Immunoblotting (repeated
three times) confirmed that siRNA downregulation of EXOSC8 resulted in increased MBP protein levels in human oligodendroglia cells. CNTR., control; NT
siRNA, non-targeting siRNA. (i) Quantification of MBP protein expression in differentiated oligodendroglia cells after EXOSC8 downregulation.
(j) Double immunolabelling of differentiated human oligodendroglia cells for MBP (green channel) and EXOSC8 (red channel). Left column: non-targeting
control transfected cells. NT siRNA, non-targeting siRNA. EXOSC8 localized to the nucleus and MBP is distributed throughout the cytosol in EXOSC8
ablated cells. Right column: EXOSC8 staining confirms successful siRNA-mediated downregulation and increased MBP expression. Scale bar, 20 mm.
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antisense morpholino oligonucleotides (MO) to downregulate the
zebrafish exosc8 gene (Gene ID:323016, mRNA:NM_001002865,
Supplementary information) in embryos from the golden strain
and from the islet-1-green fluroscent protein (GFP) transgenic
zebrafish line (Tg(islet-1:GFP)23. Confirming the efficiency of the
splice-blocking exosc8 MO, RT-PCR indicated the loss of wild-
type exosc8 transcript (Fig. 6b, Supplementary Fig. 2). In support
of the phenotype caused by the splice-blocking exosc8 MO, we
detected similar changes by using the second translation-blocking
exosc8 MO in zebrafish. Knock down of exosc8 in zebrafish
embryos resulted in a set of phenotypes ranging from mildly to
severely abnormal external morphology (Fig. 6a,c). Swimming
abilities and touch-evoked escape response at 48 h post
fertilization (hpf) were impaired even in embryos with a mild
phenotype (Supplementary videos). Importantly, downregulation
of exosc8 led to abnormal brain development in islet-1-GFP
transgenic zebrafish, which express GFP in the motor neurons of
the hindbrain. The degree of brain abnormality correlated with
the increased severity of morphant phenotype (Fig. 6d),
suggesting that Exosc8 is essential for brain development in
zebrafish. Although the recapitulation of an identical phenotype
with translation-blocking MO is in support of a specific effect in
our experiments, to exclude an off-target effect we introduced co-
injection of p53 MO to block off-target cell death.
We performed several attempts to rescue the phenotype of
MO-treated zebrafish with different doses of wild-type human
EXOSC8 mRNA. We observed a dose-dependent toxic reaction
after addition of the wild-type EXOSC8 mRNA to MO-treated
zebrafish. The reason behind the toxicity may be that an
imbalanced supply of the different exosomal proteins may have
deleterious effect on the function of the exosome, as comparative
assessment of protein abundance and localization in living cells
showed, that EXOSC8 and EXOSC9 are present in a 1:1
stoichiometry within the complex24.
Similar to the studies performed in human cells, we analyzed
AU-rich mRNAs encoding myelin proteins in exosc8 morphants
and control zebrafish embryos. Similar to the results in human
oligodendrocytes and myoblasts, mbp mRNA increased initially
(16 hpf) in exosc8 morphants, but decreased at later timepoints
(48 hpf), especially in morphants with severe phenotype, most
likely due to the loss of neuronal structures and surrounding
oligodendroglia (Fig. 7a). Previous studies25 and the ZFIN
database detected expression of mbp by in situ hybridization
during early somitogenesis at about 11 hpf (http://zfin.org/cgi-
bin/webdriver?MIval=aa-fxfigureview.apg&OID=ZDB-FIG-
050630-1515), and exosc8 expression at the 14–19 somite
stage around 16 hpf (http://zfin.org/cgi-bin/webdriver?MIval=
aa-fxallfigures.apg&OID=ZDB-PUB-040907-1&fxallfig_probe_
zdb_id=ZDB-EST-080225-97). We did not study expression of
the zebrafish smn1 gene, because in contrast to the human SMN1
zebrafish smn1 is not ARE.
We also performed whole-mount immunohistochemistry in
zebrafish larvae after exosc8 MO injection with an antibody
against the zebrafish MBP (kind gift of Prof. Talbot, Stanford). In
un-injected embryos, MBP expression at 4 days post fertilization
(dpf) was observed in the ventral hindbrain, spinal cord, along
motor axons exiting the spinal cord and the lateral line. In exosc8
morphants the MBP signal on motor axons in somites, on the
posterior lateral line and in the head was missing or interrupted
(Fig. 7b, Supplementary Fig. 3). We also performed combinatorial
labelling (BrainStain Imaging Kit, Molecular Probes) including
FluoroMyelin Green stain, which works via the high lipid content
of myelin and provided further evidence, independent from
immunostaining with MBP, that myelination is primarily
impaired in exosc8 MO downregulated zebrafish (Fig. 7c). As a
final proof of a defective myelination, electron microscopy (EM)
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injected mild, moderate and severe phenotype, respectively. Mild phenotype:
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Relative distribution of the exosc8 morphant phenotypes described above.
External morphology described in a and cranial nerve abnormalities displayed
in panel d are both taken into account in this categorization; exosc8 MO was
injected in three independent experiments into embryos of the Tg(islet-1:GFP)
strain and a total of 262 MO injected embryos were evaluated by light and
fluorescent microscopy. (d) Brain abnormalities of exosc8 morphants (Tg(islet-
1:GFP) strain) from the different phenotypes at 48 hpf: dorsal views of GFP
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embryos express GFP in cranial motor and sensory neurons and in the efferent
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neuron structure and development was detected in embryos of the normal and
mild category. Disrupted neuronal structure in the severe and in a proportion
of the moderate categories; GFP positive cells are scattered, no clear structures
are visible and overall GFP expression is reduced.
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on exosc8 MO-treated zebrafish revealed a clear defect in
myelination at 4 dpf (Fig. 7d).
Simultaneous MO knock down of zebrafish mbpa (gene ID:
326281, NC_007130.5) and exosc8 was performed to explore
whether the phenotype of exosc8 downregulated zebrafish
embryos can be rescued by knocking down mbp, which is
originally increased in exosc8 downregulated zebrafish. Survival
rate of MO injected zebrafish embryos was better in the
simultaneous mbpa, exosc8 knockdown group (73.6%) compared
with embryos treated with exosc8 MO only (53.7%) (Fig. 8a).
Furthermore, in embryos with severe phenotype the pattern of
midbrain and hindbrain nuclei was slightly more preserved in
simultaneous mbpa, exosc8 MO-treated embryos compared with
zebrafish treated with exosc8 MO only (Fig. 8b). Taken together,
these data suggest that the neuronal defect caused by exosc8
downregulation primarily impairs myelination by affecting the
regulation of mbp genes. Furthermore, we show that additional
knock down of mbp improved the survival rate and brain
structure of exosc8 MO downregulated zebrafish, suggesting that
the original increase of mbp expression may trigger downstream
events resulting in loss of MBP and impaired myelination in
zebrafish.
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Discussion
The first human disease linked to an integral exosome component
was EXOSC3 deficiency, which has been identified in pontocer-
ebellar hypoplasia (PCH) and spinal motor neuron disease
(PCH1, MIM 607596)26–28. A broader clinical spectrum was
recently suggested in patients with EXOSC3 mutations including
isolated cerebellar hypoplasia and spinal anterior horn
involvement or intellectual disability, early-onset spasticity and
cerebellar atrophy29. A severe form of PCH1 has been reported
among Czech Roma due to a founder mutation in EXOSC3
(ref. 30).
We discovered pathogenic mutations in the exosomal protein
gene EXOSC8 in 22 patients with profound infantile neurode-
generative disease combining features of cerebellar and corpus
callosum hypoplasia, hypomyelination and SMA. The similar
disease spectrum caused by the defect of a different exosome
protein suggest that impaired mRNA metabolism due to exosome
dysfunction is the major common pathomechanism. However,
while EXOSC3 mutations affect mostly spinal motor neurons and
Purkinje cells, oligodendroglia cells are also targets of mutations
in EXOSC8. It is possible that different exosome components
affecting different ARE mRNAs, potentially based on their
length9, or mRNA metabolism may have neuronal cell-type
specific differences, potentially influenced by the type or
localization of the exosome defect. However, both studies
clearly suggest the major role of ARE mRNA metabolism in
this complex neurodegenerative disease.
In support of a close interaction between EXOSC8 and
EXOSC3 within the exosome, reduced EXOSC3 protein levels
were detected in our patients carrying EXOSC8 mutations, and
also in control cells after siRNA downregulation of EXOSC8
(Supplementary Fig. 4).
Both peripheral and central myelination requires an exact ratio
of several myelin proteins31. Central nervous system myelin is a
multi-layered membrane sheath generated by oligodendrocytes
for rapid impulse propagation. It has been recently shown that
new myelin membranes are incorporated adjacent to the axon,
and simultaneously, newly formed layers extend laterally, leading
to the formation of a set of closely apposed paranodal loops32.
This model can explain the assembly of myelin as a multi-layered
structure, where increased amount of MBP, a peripheral
membrane protein, may result in premature compaction and
may block myelin growth32 or compaction at aberrant locations,
which could also be toxic for myelination22. Duplication of PLP1
is a frequent cause of PMD33–35 and a similar gene dosage effect
of PMP22 is responsible for the demyelinating peripheral
neuropathy in Charcot-Marie-Tooth disease type 1A36. A link
between ARE mRNA decay and demyelination is further
supported by the progressive leukodystrophy caused by
mutations in the AU-specific RNA binding protein (AUH)37.
We suggest that increased mRNA levels of ARE-containing
myelin proteins (MBP, MOBP) resulting from EXOSC8 deficiency
initiate a cascade of downstream events, and the disturbed
balance between ARE and non-ARE myelin components results
in demyelinating disease. Ultimately, the loss of oligodendroglia
cells leads to a secondary decrease of myelin proteins, as shown in
exosc8 MO injected zebrafish, where an initial increase, followed
by a secondary decrease of myelin proteins resulted in defective
myelination.
The genetic causes of isolated PCH are autosomal recessive
mutations in genes involved in transfer RNA splicing and
processing38. Splicing of the pre-mRNAs by the spliceosome
depend on small nuclear ribonucleoproteins, which require Spinal
Motor Neuron 1 (SMN1) protein for their assembly and defect of
SMN1 results in SMA, a leading cause of infantile mortality39.
The exact mechanisms behind the strict cell-type specific effect of
these factors involved in RNA metabolism are still unclear;
however, it is possible that some clinical presentations of EXOSC8
and EXOSC3 mutations, and potentially other human exosome
related diseases, are due to abnormal RNA splicing.
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In summary, patients with EXOSC8 mutations present with a
characteristic spectrum of overlapping phenotypes of infantile
onset hypomyelination, cerebellar hypoplasia and SMA. The
clinical presentation may depend on the type and localization of
mutations and provides a clue to unravel the complex molecular
pathways caused by the defective exosome function.
Methods
Patients. We have received informed consent from the patients (parents) included
in this study. Ethical approval was obtained from the County Durham and Tees
Valley 2 Research Ethics Committee (08/H0905/106) and from the Ethics com-
mittee of the Hebrew University Hadassah Medical School (0485-09). Written
consent to publish the photo of a patient was obtained.
Histological and biochemical analyses of skeletal muscle. Histological and
biochemical analyses of skeletal muscle were performed by standard methods40.
Autopsy staining methods. The brain and spinal cord samples were fixed in 10%
phosphate-buffered formal saline before embedding in paraffin wax. For Luxol Fast
Blue staining 10-mm sections were dehydrated and stained with Luxol Fast Blue
overnight at room temperature, and then rinsed in alcohol and water to remove
excess blue colour. The sections were differentiated with a weak solution of lithium
carbonate, followed by 70% alcohol solution. Immunohistochemistry was done
following citrate (pH 6) and EDTA (pH 8) pre-treatment for 10min. Immuno-
histochemistry was carried out on 5-mm sections with mouse monoclonal anti-
bodies that recognize MBP (1:2000 SM194R, Covance, NJ, USA) and vimentin
(1:5600 clone V9 Dako; Copenhagen, Denmark). Rabbit monoclonal antibody was
used for p62 1:150 SQTM1 (Santa Cruz Biotechnology, TX, USA). Sections were
also stained with haematoxylin. Stainings were performed on at least three different
sections.
Genetic analysis. Genome-Wide Human SNP Array 6.0 (Affymetrix) was per-
formed in pedigree 1 on six affected (P1-V:2, P1-V:10, P1-V:19, P1-V:22, P1-V:26,
P1-V:28) and one unaffected family member (P1-IV:14), and in pedigree 3 and in 2
it was performed on affected family members (P3-II:1, P3-II:3) Single nucleotide
polymorphisms were analyzed using HomozygosityMapper13. Excess
homozygosity was defined using [max_block_length¼ 1,000] and an excess
homozygosity threshold of 0.8 (80%)13. For exome sequencing genomic DNA from
patients P1-V:10, P1-V:29 from pedigree 1 and P3-II:1 from pedigree 3 was
fragmented to 150–200 bp with the use of Adaptive Focused Acoustics (Covaris);
then end-repaired, adenylated, and ligated to adaptors (Illumina Paired-End
Sample Preparation kit). Ligated libraries were hybridized with whole-exome baits
that covered 27,184 genes with modifications for the SureSelect Human All Exon
Kit Version 2 (Agilent), Illumina Paired-end Sequencing Library Version 2.0.1. The
captured fragments were purified and clonally amplified, and then sequenced on
two lanes of an Illumina Genome Analyzer IIx with the use of 75 bp paired-end
reads. Sequence was aligned to the human reference genome (UCSC hg19) with the
Burrows Wheeler Aligner41,42, then reformatted with the use of SAMtools v0.1.18
(ref. 43). Exon target sequence (93.4%) was covered by 410 reads with a mean
target depth of 121. Single base variants were identified with Varscan v2.2 (ref. 44)
and Indels were identified with Dindel v1.01 (ref. 45). Variants were annotated
using wAnnovar46. Lists of on-target variants were filtered against data from
NHLBI-6500-ESP, the 1,000 Genomes project, and the exome sequences of 334
unrelated in-house control exomes to identify rare homozygous variants with a
MAFo0.01.
Cell culture and siRNA transfection. Cultured myoblasts of patient V:10 (pedi-
gree 1) and controls were grown in skeletal muscle cell growth medium and
supplement mix (PromoCell) supplemented with 10% (v/v) foetal bovine serum
(FBS, Sigma Aldrich) and 4-mM L-glutamine (Invitrogen) and cultured as
recommended by the supplier. Fibroblasts of patient P3-II:1 were grown in high
glucose Dulbecco’s modified Eagle’s medium (DMEM, Sigma, Poole, UK) sup-
plemented with 10% FBS. Myoblasts of patient V:10 and a control cell line were
immortalized by transduction with a retroviral vector expressing the catalytic
component of human telomerase47. Silencer EXOSC8 RNA (s22370 siRNA,
Ambion–Life Technologies) was transiently transfected in control myoblasts,
fibroblasts and in M03.13 human oligodendroglia cells at a final concentration of
5 nm using Lipofectamine RNAiMAX (Invitrogen), according to the manufacturer’s
specifications. Transfections were repeated on day 3 and cells were harvested on day
6. A non-targeting SilencerSelect Negative Control (#1) was used as a control.
Human oligodendrocytic cells (MO3.13) were grown in DMEM supplemented
with 10% FBS. The human oligodendroglia cell line was received from the McGill
University, where it was originally characterized. Medium was changed every 2–3
days. MO3.13 cells were differentiated in oligodendrocyte differentiation medium
for 7 days. Each experiment was repeated at least three times.
Immunoblotting. Aliquots of total protein were loaded on 14% SDS–
polyacrylamide gel electrophoresis (SDS–PAGE), transferred to polyvinylidene
fluoride membranes and subsequently probed with a polyclonal antibody recog-
nizing EXOSC8 (Proteintech Group Inc., 11979-1-AP, 1:200) or Pierce Antibodies
(PA5-12378, 1:100, Fig. 3f) and monoclonal antibodies targeting mitochondrial
COXI (Mitosciences MS404, 0.5 mgml 1), COXII (Abcam ab110258, 1 mgml 1),
NDUFB8 (Abcam ab110242, 0.5 mgml 1), MBP (Covance SMI-94R, 1:1,000),
EXOSC3 (Proteintech Group Inc., 15062-1-AP, 1:200), GAPDH (Santa Cruz
sc25778, 1:500), porin (Abcam ab14734, 1 mgml 1) and b-actin (Sigma A1978,
0.5 mgml 1), anti-acetylated tubulin for zebrafish (Sigma, T 6793, 1:500) according
to the instructions of the suppliers. MBP for Zebrafish was a kind gift from
Prof. William Talbot. Each experiment has been repeated at least three times.
Blue native PAGE (BN–PAGE). BN–PAGE was performed as described48.
Yeast strains and culture condition. Saccharomyces cerevisiae strains used in this
study are R1158 (deletion consortium wild-type MATa his3D1 leu2D0 met15D0
ura3D0 BY4741 with TTA integrated at URA3) and RRP43 Tet-O7-promoter
mutant (referred as tetRRP43), kindly provided by T. Hughes18. The promoter-
replacement system approach allows modulating the downregulation of essential
genes by replacing the native promoter with one tetracycline-regulatable promoter
that can be repressed by addition of doxycycline to the growth medium.
Cells were cultured in yeast peptone (YP) medium (1% Bacto–yeast extract and
2% Bacto–peptone (ForMediumTM, UK))49. Various carbon sources were added at
2% (w/v) (Carlo Erba Reagents, Italy). Media were solidified with 20 g l 1 agar
(ForMediumTM, UK). For respiration and mitochondria extraction, cells were
grown to late-log phase in the YP medium supplemented with 0.6% glucose.
Oxidative growth, respiration and cytochrome spectra in yeast were performed.
Oxidative growth phenotype was performed by spotting decreasing concentrations
of yeast cells on YP medium supplemented either with 2% glucose or with 2%
glycerol. Differential spectra between reduced and oxidized cells of a suspension of
cells at 500mgml 1 (wet weight) were recorded at room temperature, using a
Cary 300 Scan spectrophotometer (Varian, Palo Alto, CA, USA). Oxygen uptake
rate was measured at 30 C using a Clark electrode in a reaction vessel of 3ml of
air-saturated respiration buffer (0.1M phthalate–NaOH, pH 5.0), 10mM glucose,
starting the reaction with the addition of 10mg of wet weight of cells50.
Mitochondrial protein synthesis in yeast was performed by standard methods51.
Gene expression studies. cDNA was generated by reverse transcription of 500 ng
of total RNA using the Superscript VILO cDNA synthesis kit (Invitrogen, 11754-
050) according to manufacturers’ instructions. qPCR (Applied Biosystems
7900HT) was performed in triplicate on cDNA using SYBR Green PCR Master
Mix (Invitrogen, 4309155). For human cells samples were normalized using the
average of three reference genes, GAPDH, b–tubulin and actin; and for zebrafish
samples were normalized to actin, EF1a and Rpl13a. Primers are shown on
Supplementary Table 4.
Measurement of EXOSC8 mRNA copy numbers. Patient and three control
fibroblast lines were grown in DMEM supplemented with 15% FBS and 1%
Penicillin/Streptomycin to semi-confluence. To half of the cultures 300mM pur-
omycin was added 6 h prior to harvesting the cells. mRNA was prepared with the
Trizole method and reverse transcribed into cDNA with random hexamers using
the Superscript II kit (Life Technologies). For qPCR detection we used SYBR Green
(Life Technologies) and a primer pair that generated a 198-bp product that
comprised all known splice isoforms of EXOSC8: forward, 50-GCATCCGTGTCGA
AAGTGC-30 ; reverse, 50-CTGGGTTCAAAACCGTGGAACC-30. The qPCR was
run on an ABI 7700 machine using the –DDCt method with HPRT: forward,
50-ACAATGCAGACTTTGCTTTCC-30 ; reverse, 50-TCAAGGGCATATCCTACA
ACAA-30) as the reference gene.
Zebrafish strains and maintenance. Zebrafish strains used in this study were the
golden strain and the islet-1-GFP transgenic line (Tg(islet-1:GFP), expressing GFP
driven by the islet-1 promoter)23. All zebrafish procedures were performed under
Home Office UK licence regulations. Zebrafish embryos were collected and raised
at 28.5 C according to standard procedures52 and staged in hpf or dpf according to
standard criteria53 PTU (0.003%; Sigma) was used to suppress pigmentation when
necessary. The p53 morpholino was purchased from Gene Tools (Pilomath, OR).
Antisense MO injections. The antisense MO to downregulate exosc8, mbpa and
mbpb expression in zebrafish was purchased from Gene Tools. The MO was
designed using the mRNA of the zebrafish exosc8 orthologue; (Gene ID: 323016,
mRNA accession number: NM_001002865) and the corresponding genomic
sequence on zebrafish chromosome 10. We designed a splice-blocking MO directed
against the splice donor site of exon 2: 50-AGATTAACTCTCACCAGAAAGCT
CC-30 and a second translation-blocking MO 50-TTTAAAACCAGCCGCCATG
ATGTTT-30 . Embryos were injected with 10–12 ng exosc8 MO. We designed a
translation-blocking MO directed against mbpa (50-GGCCATTCTAGGTGTTGA
TCTGTTC-30). Embryos were simultaneously injected with 1 ng MO, with the
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addition of 5-ng p53 MO. We also simultaneously injected mbpa (1 ng) and exosc8
(10–12 ng) MOs with 5 ng p53 in separate experiments with equal MO doses, on
the same clutch of embryos.
Three independent MO injection experiments were performed and over 300
injected embryos were evaluated in total to establish morphant phenotypes. MO
injection into embryos of the Tg(islet-1:GFP) strain were used to study brain
abnormalities, whereas embryos of the golden strain were used for whole-mount
antibody staining procedures. Zebrafish were anesthetized with Tricaine solution
and phenotyped at 48 hpf to assess brain and tail morphology. Images were
captured using a MZ16F fluorescent stereomicroscope (Leica).
RNA isolation and RT-PCR in zebrafish. RNA from zebrafish embryos and larvae
was isolated with Trizol reagent (Invitrogen) following the manufacturer’s
instructions. For RT–PCR analysis in developing zebrafish embryos and following
MO injection, RNA from B30 embryos was extracted and after cDNA synthesis
from three different MO injections. Primers used for zebrafish RT–PCR are shown
on Supplementary Table 5.
Whole-mount antibody immunofluorescence. For whole-mount immuno-
fluorescence staining, zebrafish embryos and larvae were fixed in 4% para-
formaldehyde in phosphate-buffered saline overnight at 4 C and then
permeabilized in cold acetone at  20 C. In addition, 4-dpf-old larvae were per-
meabilized with collagenase A (Roche Diagnostics, 1mgml 1) for 90min.
Embryos/larvae were blocked in 5% horse serum in phosphate-buffered saline
containing 0.1% Tween-20 (PBT). Embryos/larvae were incubated in blocking
solution containing primary antibody overnight at 4 C followed by washing sev-
eral times with PBT and incubation with secondary antibody (anti-rabbit Alexa
Fluor 594 and anti-mouse Alexa Fluor 488, Invitrogen). The primary antibodies
used in this study were a polyclonal rabbit anti-MBP antibody (1:50 dilution, a kind
gift from Prof. William Talbot, Stanford University) and a mouse monoclonal anti-
acetylated tubulin antibody (1:500 dilution, Sigma) to label axon tracts. Combi-
national staining of myelin, neurons and nuclei in zebrafish embryos was per-
formed using BrainStain Imaging Kit (Molecular Probes, B34650). Stained
embryos/larvae were imaged with a Zeiss Axio Imager microscope. Immuno-
fluorescence images were collected using a Zeiss Axio Imager Z1 fluorescence
microscope equipped with Zeiss Apotome 2 (Zeiss, Germany) in AxioVision Rel
4.9 software.
Electron microscopy. Zebrafish at 4 dpf were fixed in 2% glutaraldehyde in
sodium cacodylate buffer at 4 C overnight and suddenly washed three times
(15min each) in cacodylate buffer, and then stained with 1% osmium tetroxide
(Agar Scientific) in dH2O for 1 h. Fish were dehydrated using graded acetone (25,
50 and 75% and twice in 100%). Fish were impregnated through increasing con-
centration of resin in acetone (25, 50, 75 and 100%) and then embedded in 100%
resin at 60 C for 24 h (TAAB Lab. Equip). Ultra-thin transverse sections of
B70 nm were cut using a diamond knife on a Reichert Ultracut E ultramicrotome.
The sections were stretched with chloroform to eliminate compression and
mounted on pioloform-filmed copper grids. The grids were then stained with 2%
aqueous uranyl acetate lead citrate and subsequently examined using a Philips CM
100 Compustage (FEI) Transmission Electron Microscope and digital images were
collected using an AMT CCD camera (Deben) at the Electron Microscopy
Research Services, Newcastle University.
Statistical analysis. For the statistical analysis of qRT-PCR we used unpaired
t-test.
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